溶瘤生物科技 ONCY 深 沪
等待开盘 05-12 09:30:00 美东时间
0.8905
+0.001
+0.07%
华盛通- 最 高0.95
- 今 开0.8947
- 成交量 54.69万股
- 最 低 0.8721
- 昨 收 0.8899
- 总市值 5.15万
- 52周最高 1.51
- 市盈率 静 --
- 换手率 946.35%
- 52周最低 0.3258
- 委 比 87.55%
- 总股本 5.78万
- 历史最高 6.037
- 量 比 1.10
- 振 幅 8.75%
- 历史最低 0.3258
- 每 手 1
- 风险率 0.24%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics shares rise as pelareorep shows 19.5-month response durability and higher response rates in colorectal cancer study.
05-05 00:42
Oncolytics Biotech Concludes Patient Enrollment In GOBLET Trial
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that it has concluded enrollment in the GOBLET study, having
02-24 22:04
Oncolytics Biotech Intends To Change Jurisdiction Of Incorporation To Nevada
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced proposal to
01-09 22:07
中国科学家攻克癌症？溶瘤病毒技术已有多家上市药企涉猎
财联社3月11日讯（记者 卢阿峰）日前，在社交平台上，一则“中国科学界攻克癌症”的消息广泛流传，称“该研究成果具备诺贝尔奖的级别”，其内容直指前段时间广西医科大...
2025-03-11 20:09
Earnings Scheduled For March 7, 2025
Companies Reporting Before The Bell • Creative Media (NASDAQ:CMCT) is estimated...
2025-03-07 16:32
Editas Medicine, Inc.盘中异动 股价大跌5.18%
北京时间2024年10月08日02时30分，Editas Medicine, Inc.（EDIT.us）股票出现异动，股价快速跳水5.18%。截至发稿，该股报3.21美元/股，成交量97.6255万股，换手率1.18%，振幅6.36%。 最近的财报数据显示，该股实现营业收入513000.00美元，净利润-67.61百万美元，每股收益-0.82美元，毛利-907000.00美元，市盈率-1.38倍。 机构评级方面，在所有19家参与评级的机构中，53%的券商给予买入建议，47%的券商给予持有建议，无券商给予卖出建议。 Editas Medicine, Inc.股票所在的生物技术行业中，整体跌幅为0...
2024-10-08 02:30
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
2024-09-19 23:32
Oncolytics Reports Clinical Results From BRACELET-1 Study; Says Overall Survival Results Corroborate Results Of Previous Randomized IND-213 Breast Cancer Study
Confirmed overall response rate (ORR) was 37.5% for pelareorep + paclitaxel and 13.3% for paclitaxel. As previously reported, ORRs at week 16 (the trial's primary endpoint) in the pelareorep
2024-09-19 19:19
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech (NASDAQ:ONCY) with a Buy and maintains $5 price target.
2024-08-21 19:55
